摘要
目的观察吡格列酮治疗2型糖尿病合并早期糖尿病肾病的临床疗效。方法61例2型糖尿病合并早期糖尿病肾病患者随机分为治疗组和对照组。对照组给予基础治疗,治疗组在基础治疗上加用吡格列酮口服。疗程为12周。比较治疗前、后两组血糖(FBG)、尿白蛋白排泄率(UAER)、胰岛素抵抗指数(Homa-IR)、糖化血红蛋白(HbA1c)等指标变化。结果两组治疗后FBG、HbA1c、UAER、Homa-IR与治疗前比较,下降明显,差异有统计学意义(P<0.05);治疗后两组比较,治疗组FBG、HbA1c、UAER、Homa-IR较对照组下降更明显(P<0.05或P<0.01)。结论吡格列酮可以有效调控早期2型糖尿病肾病患者的血糖,改善胰岛素抵抗,减少尿蛋白排泄,保护肾功能。
Objective To observe the clinical effect of pioglitazone in treating type 2 diabetes mellitus （T2DM） combining early diabetic nephropathy （DN）. Methods A total of 61 T2DM patients with early DN were randomly divided into treatment group and control group. All patients were received routine medical treatment, and the treat group was also received pioglitazone. The treatment was lasted for 12 weeks. The differences of fasting blood glucose （ FBG）, urinary albumin excretion rate （UAER）, Homa insulin resistance index （Homa-IR）, glycosylated hemoglobin （HbAlc） of the two groups before and after treatment was compared. Results After the treatment, the FBG, HbAlc, UAE, and Homa-IR of the two groups decreased obviously than those before the treatment （ P 〈 0.05 ）. After treatment the FBG, HbA1 c, UAER, and Homa-IR of the treatment group decreased more significantly than those of the control group （ P 〈 0.05 ）. Conclusion Pioglitazone can control the FBG of T2DM patients with early DN effectively and decrease urine protein excretion, and can protect the renal function.
出处
《今日药学》
CAS
2009年第10期41-42,45,共3页
Pharmacy Today
关键词
吡格列酮
早期糖尿病肾病
胰岛素抵抗
pioglitazone
early diabetic nephropathy
insulin resistance
